ORXOY (Orexo AB) Ending Cash Position: $29.10 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORXOY Orexo AB ORXOY
37 GF Score
Price $1.80
GF Value $0.31
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Ending Cash Position?

Orexo AB ORXOY -14.29% 37 Ending Cash Position is $29.10 Mil as of Jun. 2026. GuruFocus rates ORXOY with a GF Score™ of 37/100 and a GF Value™ of $0.31 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Orexo AB's Ending Cash Position for the quarter that ended in Jun. 2026 was $29.10 Mil.

Orexo AB's quarterly Ending Cash Position declined from Dec. 2025 ($98.18 Mil) to Mar. 2026 ($41.45 Mil) and declined from Mar. 2026 ($41.45 Mil) to Jun. 2026 ($29.10 Mil).

Orexo AB's annual Ending Cash Position declined from Dec. 2023 ($16.67 Mil) to Dec. 2024 ($11.22 Mil) but then increased from Dec. 2024 ($11.22 Mil) to Dec. 2025 ($98.18 Mil).

Orexo AB Ending Cash Position Related Terms

Orexo AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Orexo AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Ending Cash Position Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.46 12.74 16.67 11.22 98.18

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.70 11.27 98.18 41.45 29.10
ORXOY
37GF Score
Orexo AB ORXOY
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Orexo AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=123.397+-25.221
=98.18

Orexo AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=39.126+-10.026
=29.10

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $29.10 Mil mean?
Orexo AB (ORXOY) has a Ending Cash Position of $29.10 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Orexo AB and its competitors.
Is Orexo AB's Ending Cash Position too high?
Orexo AB's current Ending Cash Position is $29.10 Mil. Overall, Orexo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Ending Cash Position compare to ZTS and UTHR?
Orexo AB's Ending Cash Position of $29.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Orexo AB and its competitors. Orexo AB's current Ending Cash Position is $29.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $1.80 — trading 480.6% above its estimated fair value. The current Ending Cash Position is $29.10 Mil. Orexo AB's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Ending Cash Position is $29.10 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOY) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $1.80 is trading 480.6% above its estimated GF Value™ of $0.31. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOY:

  • Ending Cash Position: $29.10 Mil
  • GF Value™: $0.31 vs. price of $1.80 (480.6% above fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score

Get the complete analysis for ORXOY

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.31
GF Value